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We thank Prabhavathi Fernandes for his interest in our work on pneumonia-related research 
investments,1 and welcome his response.2 It is very encouraging to see described the 
investments of Cempra and the progress made in developing treatments for pneumococcal 
pneumonia, alongside the success of pneumococcal vaccination programmes3. 
We would like to clarify Dr Fernandes’ point regarding ‘the authors are incorrect in stating 
that investment has been lacking for the development of antibiotics to treat pneumonia’. Our 
reference to a lack of investment in clinical trials and antimicrobial resistance is clearly a 
conclusion reached from within the confines of our dataset, that of public and philanthropic 
awards to UK institutions; here the evidence is really unequivocal, there is precious little 
research investment in the UK in the area of pneumonia and other respiratory infections,4 
hence our point that there is a real need to fill in the gaps in knowledge across all sources of 
investment.   
There are two key areas where we are looking to expand the Research Investments in 
Global Health analyses- i) to go beyond the UK, and include analyses of infectious disease 
awards made to institutions in other countries (particularly the USA); ii) to engage with the 
private sector globally, and be able to incorporate pharmaceutical and biotechnology 
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research investment information into our analyses with the same level of detail we have 
awards from the public and charitable sectors.  
On this latter point, our thanks again to Dr Fernandes for raising the issue of private sector 
investment, and we will be proactive in seeking out fruitful engagement on this subject that 
will benefit senior global policymakers, funders, and research institutions.  
 
1 Head MG, Fitchett JR, Newell M-L, Scott JAG, Clarke SC, Atun R. Investment in 
pneumonia and pneumococcal research. Lancet Infect Dis 2014; 14: 1037–8. 
2 Fernandes P. Investment in antibiotics against pneumonia. Lancet Infect Dis 2015; 
15: 376. 
3 Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of 
the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in 
England and Wales 4 years after its introduction: an observational cohort study. 
Lancet Infect Dis 2015; 15: 535–43. 
4 Head MG, Fitchett JR, Cooke MK, et al. Investments in respiratory infectious disease 
research 1997-2010: a systematic analysis of UK funding. BMJ Open 2014; 4: 
e004600–e004600.  
 
 
 
 
